226 related articles for article (PubMed ID: 11679926)
1. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
Duan C; Poticha D; Stoeckli TC; Petropoulos CJ; Whitcomb JM; McHenry CS; Kuritzkes DR
J Infect Dis; 2001 Nov; 184(10):1336-40. PubMed ID: 11679926
[TBL] [Abstract][Full Text] [Related]
2. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
[TBL] [Abstract][Full Text] [Related]
3. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
5. Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.
Milazzo L; Rusconi S; Testa L; La Seta-Catamancio S; Galazzi M; Kurtagic S; Citterio P; Gianotto M; Grassini A; Adorni F; d'Arminio-Monforte A; Galli M; Moroni M
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):101-3. PubMed ID: 10534153
[No Abstract] [Full Text] [Related]
6. Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
Jeffrey JL; Feng JY; Qi CC; Anderson KS; Furman PA
J Biol Chem; 2003 May; 278(21):18971-9. PubMed ID: 12651859
[TBL] [Abstract][Full Text] [Related]
7. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.
Lennerstrand J; Hertogs K; Stammers DK; Larder BA
J Virol; 2001 Aug; 75(15):7202-5. PubMed ID: 11435603
[TBL] [Abstract][Full Text] [Related]
8. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.
Boyer PL; Gao HQ; Clark PK; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2001 Jul; 75(14):6321-8. PubMed ID: 11413298
[TBL] [Abstract][Full Text] [Related]
9. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
Fletcher CV; Kawle SP; Kakuda TN; Anderson PL; Weller D; Bushman LR; Brundage RC; Remmel RP
AIDS; 2000 Sep; 14(14):2137-44. PubMed ID: 11061655
[TBL] [Abstract][Full Text] [Related]
10. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Moore JD; Acosta EP; Johnson VA; Bassett R; Eron JJ; Fischl MA; Long MC; Kuritzkes DR; Sommadossi JP
Antivir Ther; 2007; 12(6):981-6. PubMed ID: 17926654
[TBL] [Abstract][Full Text] [Related]
11. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
Rusconi S; De Pasquale MP; Milazzo L; Kurtagic S; Bulgheroni E; Citterio P; Galazzi M; La Seta Catamancio S; Galli M
Antivir Ther; 1998; 3(4):203-7. PubMed ID: 10682139
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.
Dumond JB; Yang KH; Kendrick R; Reddy YS; Kashuba AD; Troiani L; Bridges AS; Fiscus SA; Forrest A; Cohen MS
Antimicrob Agents Chemother; 2015 Oct; 59(10):6395-401. PubMed ID: 26239974
[TBL] [Abstract][Full Text] [Related]
13. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.
Lim SE; Copeland WC
J Biol Chem; 2001 Jun; 276(26):23616-23. PubMed ID: 11319228
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates.
Uckun FM; Pendergrass S; Qazi S; Venkatachalam TK
Arzneimittelforschung; 2004; 54(1):69-77. PubMed ID: 14979612
[TBL] [Abstract][Full Text] [Related]
15. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD
J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
[TBL] [Abstract][Full Text] [Related]
17. Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors.
Hurwitz SJ; Schinazi RF
Antiviral Res; 2002 Nov; 56(2):115-27. PubMed ID: 12367718
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.
Moore JD; Valette G; Darque A; Zhou XJ; Sommadossi JP
J Am Soc Mass Spectrom; 2000 Dec; 11(12):1134-43. PubMed ID: 11118121
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
20. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
Merrill DP; Moonis M; Chou TC; Hirsch MS
J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
